Arbutus Biopharma Corp
NASDAQ:ABUS
Arbutus Biopharma Corp
Cash from Investing Activities
Arbutus Biopharma Corp
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Cash from Investing Activities
$50.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Arbutus Biopharma Corp's Cash from Investing Activities?
Cash from Investing Activities
50.8m
USD
Based on the financial report for Dec 31, 2023, Arbutus Biopharma Corp's Cash from Investing Activities amounts to 50.8m USD.